<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

BXL 628 - Elocalcitol | RO 26-9228

產(chǎn)品貨號

Axon 1676 CAS [199798-84-0] MF C29H43FO2MW 442.65 Purity: 99% Optical purity: Optically pure Soluble in DMSO and Ethanol Description A vitamin D3 analog having agonistic activities at vitamin D receptor (VDR); BXL-628 inhibits prostate cell growth and RhoA/Rho-kinase signaling, a calcium sensitizing pathway; having anti-proliferative and anti-inflammatory properties in benign prostatic hyperplasia (BPH) treatment References Certificates Categories Extra info C Crescioli et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 2004, 150(4), 591-603. ? E Colli et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006, 49(1), 82-86. ? A Morelli et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007, 67(3), 234-247. ? G Penna et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009, 69(5), 480-493. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Pain & Inflammation Stem Cell Endocrinology VDR NR1I Vitamin D receptor (VDR) agonist Chemical name (1R,5S,Z)-3-((E)-2-((3aS,7aS)-3-((S,E)-6-ethyl-6-hydroxyoct-4-en-2-yl)-3a-methyl-3a,4,5,6-tetrahydro-1H-inden-7(7aH)-ylidene)ethylidene)-5-fluoro-4-methylenecyclohexanol Parent CAS No. [199798-84-0] Order Size Unit Price Stock 2 mg €165.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

BXL 628 - Elocalcitol | RO 26-9228

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1676

CAS [199798-84-0]

MF C29H43FO2
MW 442.65

Purity: 99%
Optical purity: Optically pure
Soluble in DMSO and Ethanol

BXL 628

Description

A vitamin D3 analog having agonistic activities at vitamin D receptor (VDR); BXL-628 inhibits prostate cell growth and RhoA/Rho-kinase signaling, a calcium sensitizing pathway; having anti-proliferative and anti-inflammatory properties in benign prostatic hyperplasia (BPH) treatment

C Crescioli et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 2004, 150(4), 591-603.

E Colli et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006, 49(1), 82-86.

A Morelli et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007, 67(3), 234-247.

G Penna et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009, 69(5), 480-493.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Pain & Inflammation Stem Cell Endocrinology VDR NR1I

Vitamin D receptor (VDR) agonist

Chemical name

(1R,5S,Z)-3-((E)-2-((3aS,7aS)-3-((S,E)-6-ethyl-6-hydroxyoct-4-en-2-yl)-3a-methyl-3a,4,5,6-tetrahydro-1H-inden-7(7aH)-ylidene)ethylidene)-5-fluoro-4-methylenecyclohexanol

Parent CAS No.

[199798-84-0]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>